Literature DB >> 9619830

Prognostic significance of allelic losses in primary melanoma.

E Healy1, C Belgaid, M Takata, D Harrison, N W Zhu, D A Burd, H S Rigby, J N Matthews, J L Rees.   

Abstract

Loss of genetic material, including loss of loci on chromosome arms 6q, 9p, and 10q, occurs frequently in cutaneous melanoma but infrequently in benign melanocytic nevi or other melanocytic lesions, suggesting that these genetic alterations are important in the development and progression of melanoma. To examine whether allelic loss is of prognostic importance in melanoma, disease-free survival was related to loss of heterozygosity on 6q, 9p and 10q in 83 individuals with sporadic primary cutaneous melanoma. Loss of chromosome arms 6q and 10q were each significantly associated with a poorer clinical outcome (P=0.013 and P=0.001 respectively). In a subgroup of 41 subjects whose primary tumours were allelotyped, the fractional allelic loss (FAL) at 39 autosomal arms also significantly correlated with disease-free survival (P=0.013), with an increase in FAL associated with a poorer outcome; this association remained significant when controlled for tumour thickness (P=0.035). In addition, a greater proportion of cells were immunopositive for Ki67 antigen, p53 and p21WAF1 protein in the primary melanomas than in the benign melanocytic nevi, however, only p53 over-expression was significantly associated with improved survival (P=0.041).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619830     DOI: 10.1038/sj.onc.1200203

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas.

Authors:  H Dannenberg; E J Speel; J Zhao; P Saremaslani; E van Der Harst; J Roth; P U Heitz; H J Bonjer; W N Dinjens; W J Mooi; P Komminoth; R R de Krijger
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Liquid Biopsies for Assessing Metastatic Melanoma Progression.

Authors:  Kelly Huynh; Dave S B Hoon
Journal:  Crit Rev Oncog       Date:  2016

4.  Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.

Authors:  M S Shin; W S Park; S Y Kim; H S Kim; S J Kang; K Y Song; J Y Park; S M Dong; J H Pi; R R Oh; J Y Lee; N J Yoo; S H Lee
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

5.  Molecular clonality of in-transit melanoma metastasis.

Authors:  T Nakayama; B Taback; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 6.  Prognostic molecular biomarkers for cutaneous malignant melanoma.

Authors:  Ryo Tanaka; Kazuo Koyanagi; Norihiko Narita; Christine Kuo; Dave S B Hoon
Journal:  J Surg Oncol       Date:  2011-05-09       Impact factor: 3.454

Review 7.  Transcription factors and other dysregulated proteins in melanoma prognosis.

Authors:  J M Karjalainen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

8.  Melanoma biomarkers: Vox clamantis in deserto (Review).

Authors:  Mays Al-Shaer; Divya Gollapudi; Chris Papageorgio
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

Review 9.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

10.  LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.

Authors:  Jacky T Yeung; Ronald L Hamilton; Koji Ohnishi; Maki Ikeura; Douglas M Potter; Marina N Nikiforova; Soldano Ferrone; Regina I Jakacki; Ian F Pollack; Hideho Okada
Journal:  Clin Cancer Res       Date:  2013-02-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.